Does Metoprolol Cause Hyperkalemia?
Yes, metoprolol and other beta-blockers can cause hyperkalemia by decreasing potassium excretion, though this effect is generally modest and clinically significant primarily in patients with additional risk factors such as renal impairment, concurrent use of RAAS inhibitors, or diabetes.
Mechanism and Evidence
Beta-blockers, including metoprolol, are explicitly listed among drugs that cause hyperkalemia through decreased potassium excretion 1. The mechanism involves inhibition of the renin-angiotensin-aldosterone system and reduced cellular potassium uptake 2.
Interestingly, one older study showed metoprolol actually increased serum potassium from 4.11 to 4.27 mmol/L in acute MI patients within the first day of treatment 3. A case report documented asymptomatic hyperkalemia (5.6-5.7 mEq/L) induced by metoprolol in an elderly patient with diabetes and stage III renal insufficiency, which normalized upon discontinuation but recurred with carvedilol, confirming this is a class effect of beta-blockers 4.
Clinical Context and Risk Stratification
The hyperkalemia risk from metoprolol alone is relatively low in patients with normal renal function. However, risk increases substantially when combined with:
- Renal impairment (eGFR <60 mL/min/1.73 m²) 1, 5
- RAAS inhibitors (ACE inhibitors, ARBs, aldosterone antagonists) 1
- Diabetes mellitus 1, 5
- Advanced age 5
- NSAIDs or other potassium-retaining drugs 1, 2
The 2018 ESC expert consensus explicitly warns against routine triple combination therapy with ACE inhibitors, ARBs, and aldosterone antagonists due to hyperkalemia risk 6, and beta-blockers add another layer of concern in this context.
Monitoring Recommendations
For patients on metoprolol with risk factors:
- Check potassium and renal function at baseline
- Recheck within 3 days and at 1 week after initiation 6, 7
- Monthly monitoring for first 3 months, then every 3 months 6, 7
- More frequent monitoring if eGFR <45 mL/min/1.73 m² or when adding/adjusting RAAS inhibitors 5
Management Approach
When hyperkalemia develops (K+ >5.5 mEq/L):
- Mild hyperkalemia (5.0-5.5 mEq/L): Continue metoprolol with dietary potassium restriction and close monitoring 1
- Moderate hyperkalemia (5.5-6.0 mEq/L): Consider dose reduction of metoprolol or other contributing agents; stop potassium supplements 6, 7
- Severe hyperkalemia (>6.0 mEq/L): Temporarily discontinue metoprolol and other potassium-retaining drugs; implement acute treatment protocols 1
Critical caveat: Do not permanently discontinue beta-blockers in heart failure patients due to hyperkalemia without attempting dose optimization or using newer potassium binders (sodium zirconium cyclosilicate, patiromer), as beta-blocker discontinuation increases mortality risk 1, 5, 8.
Practical Considerations
The FDA label for metoprolol does not specifically list hyperkalemia as a common adverse effect 9, reflecting that this is typically a modest effect in isolation. However, the 2018 ESC guidelines 1 and multiple reviews 2, 10 clearly identify beta-blockers as contributing to hyperkalemia, particularly in polypharmacy scenarios common in cardiovascular disease management.
Bottom line: Metoprolol causes hyperkalemia through a class effect of beta-blockade, but this is rarely problematic as monotherapy in patients with normal renal function. The real clinical concern emerges in patients with multiple risk factors or concurrent RAAS inhibitor therapy, where vigilant monitoring and proactive management strategies are essential to maintain life-saving medications.